CN111909869A - 植物乳杆菌y44及其在制备缓解肥胖或抗高血脂症药物或保健品中的应用 - Google Patents
植物乳杆菌y44及其在制备缓解肥胖或抗高血脂症药物或保健品中的应用 Download PDFInfo
- Publication number
- CN111909869A CN111909869A CN202010728709.9A CN202010728709A CN111909869A CN 111909869 A CN111909869 A CN 111909869A CN 202010728709 A CN202010728709 A CN 202010728709A CN 111909869 A CN111909869 A CN 111909869A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- obesity
- mice
- preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 48
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 48
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 48
- 208000008589 Obesity Diseases 0.000 title claims abstract description 21
- 235000020824 obesity Nutrition 0.000 title claims abstract description 21
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 title claims abstract description 7
- 229940079593 drug Drugs 0.000 title abstract description 6
- 244000005709 gut microbiome Species 0.000 claims abstract description 4
- 235000009200 high fat diet Nutrition 0.000 claims description 17
- 241000894006 Bacteria Species 0.000 claims description 9
- 210000001072 colon Anatomy 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 230000009286 beneficial effect Effects 0.000 claims description 3
- 230000006020 chronic inflammation Effects 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 208000027244 Dysbiosis Diseases 0.000 claims description 2
- 230000007140 dysbiosis Effects 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 2
- 230000001315 anti-hyperlipaemic effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 12
- 210000004185 liver Anatomy 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 230000000813 microbial effect Effects 0.000 abstract description 6
- 238000013218 HFD mouse model Methods 0.000 abstract description 5
- 230000002757 inflammatory effect Effects 0.000 abstract description 4
- 230000006372 lipid accumulation Effects 0.000 abstract description 3
- 235000019786 weight gain Nutrition 0.000 abstract description 3
- 102000000591 Tight Junction Proteins Human genes 0.000 abstract description 2
- 108010002321 Tight Junction Proteins Proteins 0.000 abstract description 2
- 230000004584 weight gain Effects 0.000 abstract description 2
- 241000736262 Microbiota Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 28
- 210000004379 membrane Anatomy 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000004162 Claudin-1 Human genes 0.000 description 4
- 108090000600 Claudin-1 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000003940 Occludin Human genes 0.000 description 4
- 108090000304 Occludin Proteins 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 238000003794 Gram staining Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000192142 Proteobacteria Species 0.000 description 2
- 208000021017 Weight Gain Diseases 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- YZEZMSPGIPTEBA-UHFFFAOYSA-N 2-n-(4,6-diamino-1,3,5-triazin-2-yl)-1,3,5-triazine-2,4,6-triamine Chemical compound NC1=NC(N)=NC(NC=2N=C(N)N=C(N)N=2)=N1 YZEZMSPGIPTEBA-UHFFFAOYSA-N 0.000 description 1
- 206010000188 Abnormal weight gain Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000177578 Bacterium linens Species 0.000 description 1
- 235000012539 Bacterium linens Nutrition 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108050009302 Claudin Proteins 0.000 description 1
- 102000002029 Claudin Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008951 colonic inflammation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- CDUFCUKTJFSWPL-UHFFFAOYSA-L manganese(II) sulfate tetrahydrate Chemical compound O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O CDUFCUKTJFSWPL-UHFFFAOYSA-L 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种植物乳杆菌Y44及其在制备缓解肥胖或抗高血脂症药物或保健品中的应用，属于微生物应用技术领域。使本发明提供的植物乳杆菌Y44可以显著缓解体重增加，减少肝脏及血液中的脂质积累，增加肠道紧密连接蛋白的表达，降低肠道炎症蛋白的表达，并且调节了高脂膳食小鼠的肠道微生物群，增加了微生物群的多样性。具有很好的应用前景。
Description
技术领域
本发明涉及一种植物乳杆菌Y44及其在制备缓解肥胖或抗高血脂症药物或保健品中的应用，属于微生物技术领域。
背景技术
随着社会的发展，人们的生活方式及膳食结构的改变导致摄入高热量食物，运动量减少，最终造成肥胖。肥胖是体内脂肪过度积累导致体重异常增长的一种代谢紊乱状态。其中肠道菌群与肥胖有密不可分的关系，肥胖降低肠道微生物多样性及丰富度，使一些有害菌增加并产生内毒素，经过体液循环最终造成全身慢性炎症。
益生菌是活的微生物，通过摄入一定量会对宿主产生有益作用。它们可以调节肠道微生态，增加肠道微生物多样性，使肠道菌群趋于正常化。通过定殖在肠道内增加肠道蠕动性，在代谢过程中产生短链脂肪酸，进而改善肥胖引起的脂代谢紊乱。摄食某些乳杆菌属细菌可以帮助宿主缓解高脂膳食引起的肝脏脂肪积累、高血脂症和慢性炎症。
发明内容
本发明提供一种植物乳杆菌(Lactobacillus plantarum)Y44，该植物乳杆菌(Lactobacillus plantarum)Y44已于2018年8月21日，保藏于中国典型培养物保藏中心，菌株保藏号为CCTCC NO：M 2018558。
本发明的目的之二是提供植物乳杆菌(Lactobacillus plantarum)Y44在制备用于缓解肥胖或抗高血脂症的药物或保健品中的应用。
进一步地，上述技术方案中，所述缓解肥胖包括缓解宿主摄食高脂膳食引起的体重及脏器脂肪指数的增加。
进一步地，上述技术方案中，所述抗高血脂症包括原发性高血脂症和继发性高血脂症。
进一步地，上述技术方案中，所述缓解肥胖包括恢复高脂膳食引起的肠道微生物群失调，减少有害菌丰度、增加有益菌丰度。
进一步地，上述技术方案中，所述缓解肥胖症状包括降低肥胖引起的慢性结肠炎症。
附图说明
图1为植物乳杆菌Y44显微镜图片(100×10)。
图2为植物乳杆菌Y44对高脂膳食小鼠体重。
图3为植物乳杆菌Y44对高脂膳食小鼠体重增加量的影响。
图4为植物乳杆菌Y44对高脂膳食小鼠脏器指数的影响。
图5为植物乳杆菌Y44对高脂膳食小鼠血清血脂含量的影响。
图6为植物乳杆菌Y44对高脂膳食小鼠肝脏结构染色的影响。
图7为植物乳杆菌Y44对高脂膳食小鼠结肠紧密连接蛋白含量的影响，A为定性分析结果，B为定量分析结果。
图8为植物乳杆菌Y44对高脂膳食小鼠结肠炎症蛋白含量的影响，A为定性分析结果，B为定量分析结果。
图9为植物乳杆菌Y44对高脂膳食小鼠肠道微生物门水平的影响，A为门水平热图，B为Firmicutes/Bacteroidetes比值，C为Proteobacteria相对丰度；ND表示正常组，HFD表示高脂组，HFD-L表示低剂量组，HFD-H表示高剂量组；组间不同小写字母表示显著差异(p<0.05)。
图10为植物乳杆菌Y44对高脂膳食小鼠肠道微生物科水平的影响。
具体实施方式
下述非限定性实施例可以使本领域的普通技术人员更全面地理解本发明，但不以任何方式限制本发明。
实施例1菌株培养
本发明的植物乳杆菌Y44在MRS培养基中进行培养活化，具体步骤如下：
a、菌株培养方法
(1)MRS培养基制备
按照20g/L葡萄糖，10g/L蛋白胨，5g/L酵母膏，10g/L牛肉膏，1mL吐温-80，2g/L磷酸氢二钾，2g/L柠檬酸二铵，5g/L乙酸钠，0.58g/L七水硫酸镁，0.25g/L四水硫酸锰，称取这些原料，混合均匀，将得到的混合物混溶于去离子水中，得到的溶液在温度121℃下灭菌20min，得到所述的MRS培养基。
植物乳杆菌Y44划线接种于含有2％琼脂的步骤(1)培养基中，在温度37℃下厌氧培养48h～72h，挑取单菌落，进行革兰氏染色，采用显微镜进行形态学观察，同时进行过氧化氢酶试验，微生物菌种的移接的所有操作，均应在无菌环境下严格的无菌操作。
b、菌株染色
采用革兰氏染色法对菌株染色，镜检时先用低倍，再用高倍，最后用油镜观察，并判断菌体的革兰氏染色反应性。菌体被染成蓝紫色的是革兰氏阳性菌，被染成红色的为革兰氏阴性菌。
c、菌株过氧化氢酶试验
接种环挑取上述革兰氏染色阳性菌株于含有3％过氧化氢溶液液滴的载玻片上，如有大量气泡产生为阳性，否则为阴性。
将革兰氏染色阳性、过氧化氢酶试验阴性的菌暂定名为乳酸菌。将菌株接种于MRS液体培养基中，在温度37℃下培养24h-48h后，委托大连宝生物公司进行16S rDNA测序鉴定，序列如SEQ ID NO.1所示，鉴定结果为植物乳杆菌(Lactobacillus plantarum)。植物乳杆菌(Lactobacillus plantarum)Y44的显微镜图片(100×10)如图1所示。
d、菌株保藏
所述菌株保藏于中国典型培养物保藏中心(简称CCTCC，地址：武汉市武昌珞珈山，中国典型培养物保藏中心，邮编430072)。植物乳杆菌(Lactobacillus plantarum)Y44的菌种保藏号为CCTCC NO：M 2018558，保藏日期为2018年8月21日，分类命名为植物乳杆菌(Lactobacillus plantarum)，菌株名称为Y44。
实施例2小鼠饲养及肥胖模型的建立
(1)样品制备
取植物乳杆菌(Lactobacillus plantarum)Y44(以下用Y44表示)于MRS培养基中活化3次。活化后的菌株经平板划线纯化，挑取单一菌落接种于MRS培养基，以1％(V/V)接种量于MRS培养液，37℃培养18h，连续传代3次。活化的菌株利用0.85％生理盐水清洗3次，重悬至0.85％生理盐水中，调整Y44浓度为109cfu/mL和107cfu/mL。
(2)动物分组
六周龄的雄性C57BL/6小鼠适应性饲养一周后，随机分组，每组3只。正常组(ND组)小鼠喂食正常饲料(10％的能量来源于脂肪，购自北京华阜康公司，货号H10010)每日灌胃生理盐水，高脂组(HFD组)小鼠喂食高脂饲料(60％能量来源于脂肪，购自北京华阜康公司，货号H10060)每日灌胃生理盐水，低剂量组(HFD-L组)喂食高脂饲料每日灌胃灌胃107cfu/mL植物乳杆菌(Lactobacillus plantarum)Y44，高剂量组(HFD-H组)喂食高脂饲料每日灌胃109cfu/mL植物乳杆菌(Lactobacillus plantarum)Y44，实验一共进行12周。
实施例3植物乳杆菌Y44缓解高脂膳食小鼠体重及脏器指数的增加
通过记录小鼠1-12周体重变化，对小鼠体重从第一周到第十二周体重增加量以及对小鼠肝脏、附睾脂肪、肾周脂肪的重量进行称重。结果如图2～图4所示，结果显示，植物乳杆菌Y44能够显著缓解高脂膳食小鼠体重的增加并且显著降低高脂膳食小鼠肝脏、附睾脂肪及肾周脂肪的重量。
实施例4植物乳杆菌Y44降低高脂膳食小鼠血清血脂含量
处死小鼠后取小鼠肝脏，按照试剂盒说明书的方法测定小鼠肝脏中甘油三酯(TG)、胆固醇(TC)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)的含量。甘油三酯试剂盒(A110-1，南京建成生物工程研究所)；胆固醇试剂盒(A111-1，南京建成生物工程研究所)；低密度脂蛋白胆固醇试剂盒(A113-1，南京建成生物工程研究所)；高密度脂蛋白胆固醇试剂盒(A112-1，南京建成生物工程研究所)。实验结果如图5所示，结果显示，植物乳杆菌Y44能够显著降低高脂膳食小鼠甘油三酯、胆固醇、低密度脂蛋白的含量，显著升高高密度脂蛋白的含量。
实施例5植物乳杆菌Y44减少小鼠肝脏脂质积累
处死小鼠后取小鼠肝脏用4％多聚甲醛进行固定、包埋、切片以及H&E染色，实验结果如图6所示，染色结果显示低剂量及高剂量组脂肪小泡比高脂组小并且数量明显少于高脂组。证明植物乳杆菌Y44能有效减少小鼠肝脏脂质积累。
实施例6植物乳杆菌Y44调节结肠炎症蛋白及紧密连接蛋白表达的功能分析处死小鼠后，分别取出四组小鼠结肠并且进行蛋白免疫印迹实验(western-blot)。
(1)组织蛋白的提取：称取0.1g结肠加入900μL RIPA裂解液于带磨珠的匀浆管中，通过组织匀浆器进行低温匀浆，充分匀浆后，匀浆液经13000g，4℃离心15min后取上清液分装-80℃冻存。
(2)蛋白定量：上清液按照北京索莱宝科技有限公司提供的BCA试剂盒的方法进行蛋白质的定量，计算出蛋白量后，用PBS将蛋白浓度调一致，然后经过计算加入一定体积的5×loading buffer，沸水浴变性5min，待温度降至室温后，-80℃保存。
(3)SDS-PAGE凝胶电泳
选用12％的分离胶和5％的浓缩胶进行电泳。两块板的电流为16mA—32mA，蛋白质上样量为30μg。
(4)湿法转膜
将跑好的胶放到转膜液中备用，同时注意胶的正反面。将PVDF膜裁剪好并做好标记，用纯甲醇活化30s后，置于转膜液中浸泡10min。电泳结束前，将两片海绵、六片滤纸、玻璃棒、切胶刀提前放到转膜液中浸泡。浸泡结束后，“三明治”夹膜。夹子黑下白上，依次放置海绵、三次滤纸、凝胶、PVDF膜、三层滤纸和海绵，每放置一层要赶净气泡，夹好后置于转膜槽内，黑负白正，转膜槽内加入转膜液，准备好冰水降温，开始转膜。220mA转1h。
(5)封闭：PVDF膜放到5％脱脂奶粉TBST溶液中，摇床封闭2h。
(6)洗膜：用TBST溶液洗膜3次，洗掉表面奶粉即可。
(7)一抗孵育及洗膜：将occludin、claudin-1、p38、phospho-p38以及β-actin分别用不同的一抗孵育，4℃过夜(一抗稀释按1:1000配制)后TBST洗5次，每次摇5min。
(8)二抗孵育及洗膜：将occludin、claudin-1、p38、phospho-p38用山羊抗兔孵育，β-actin用山羊抗鼠孵育，室温孵育1h后TBST洗5次，每次摇5min。再用TBS洗一遍，然后可以浸泡在TBS中。
(9)化学发光成像：取等量ECL的A液、B液(美仑公司)，混合后均匀覆盖膜1min，至于化学曝光仪器中进行曝光，最后得到曝光条带。
定性结果如图7所示，定量结果如图8所示，实验结果显示，与高脂组相比，低剂量组及高剂量组的紧密连接蛋白occludin、claudin-1发生上调，而phospho-p38发生了下调。证明植物乳杆菌Y44可以显著升高结肠紧密连接蛋白occludin、claudin-1的表达，显著降低炎症蛋白phospho-p38的表达，增强小鼠肠道屏障功能。
实施例7植物乳杆菌Y44调节高脂膳食小鼠肠道菌群的功能分析
(1)DNA提取及PCR扩增
根据
soil DNA kit(Omega Bio-tek,Norcross,GA,U.S.)说明书进行微生物群落总DNA抽提，使用1％的琼脂糖凝胶电泳检测DNA的提取质量，使用NanoDrop2000测定DNA浓度和纯度；使用SEQ ID NO.2：338F(5’-ACTCCTACGGGAGGCAGCAG-3’)和SEQ IDNO.3：806R(5’-GGACTACHVGGGTWTCTAAT-3’)对16S rRNA基因V3-V4可变区进行PCR扩增，扩增程序如下：95℃预变性3min，27个循环(95℃变性30s，55℃退火30s,72℃延伸45s)，然后72℃稳定延伸10min，最后在10℃进行保存(PCR仪：ABI 
9700型)。PCR反应体系为：5×TransStart FastPfu缓冲液4μL，2.5mM dNTPs 2μL，上游引物：SEQ ID NO.2(5μM)0.8μL，下游引物：SEQ ID NO.3(5μM)0.8μL,TransStart FastPfu DNA聚合酶0.4μL，模板DNA 10ng，补足至20μL。每个样本3个重复。
(2)Illumina Miseq测序
将同一样本的PCR产物混合后使用2％琼脂糖凝胶回收PCR产物，利用AxyPrep DNAGel Extraction Kit(Axygen Biosciences,Union City,CA,USA)进行回收产物纯化，2％琼脂糖凝胶电泳检测，并用QuantusTMFluorometer(Promega,USA)对回收产物进行检测定量。使用NEXTFLEX Rapid DNA-Seq Kit进行建库:(1)接头链接；(2)使用磁珠筛选去除接头自连片段；(3)利用PCR扩增进行文库模板的富集；(4)磁珠回收PCR产物得到最终的文库。利用Illumina公司的Miseq PE300平台进行测序(上海美吉生物医药科技有限公司)。原始数据上传至NCBI SRA数据库。
结果显示与高脂组相比，植物乳杆菌Y44增加高脂膳食小鼠肠道微生物多样性(表1)，并且在科水平上(图9～图10)增加了乳杆菌的含量，减少有害菌的含量。证明植物乳杆菌Y44可以调节小鼠肠道微生物群，使肠道菌群趋于正常组小鼠。
表1植物乳杆菌Y44对高脂膳食小鼠粪便肠道微生物多样性的影响。
序列表
<110> 大连工业大学
<120> 植物乳杆菌Y44及其在制备缓解肥胖或抗高血脂症药物或保健品中的应用
<130> 2020
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1546
<212> DNA
<213> 植物乳杆菌(Lactobacillus plantarum)
<400> 1
attaatttga gagtttgatc ctggctcagg acgaacgctg gcggcgtgcc taatacatgc 60
aagtcgaacg aactctggta ttgattggtg cttgcatcat gatttacatt tgagtgagtg 120
gcgaactggt gagtaacacg tgggaaacct gcccagaagc gggggataac acctggaaac 180
agatgctaat accgcataac aacttggacc gcatggtccg agtttgaaag atggcttcgg 240
ctatcacttt tggatggtcc cgcggcgtat tagctagatg gtggggtaac ggctcaccat 300
ggcaatgata cgtagccgac ctgagagggt aatcggccac attgggactg agacacggcc 360
caaactccta cgggaggcag cagtagggaa tcttccacaa tggacgaaag tctgatggag 420
caacgccgcg tgagtgaaga agggtttcgg ctcgtaaaac tctgttgtta aagaagaaca 480
tatctgagag taactgttca ggtattgacg gtatttaacc agaaagccac ggctaactac 540
gtgccagcag ccgcggtaat acgtaggtgg caagcgttgt ccggatttat tgggcgtaaa 600
gcgagcgcag gcggtttttt aagtctgatg tgaaagcctt cggctcaacc gaagaagtgc 660
atcggaaact gggaaacttg agtgcagaag aggacagtgg aactccatgt gtagcggtga 720
aatgcgtaga tatatggaag aacaccagtg gcgaaggcgg ctgtctggtc tgtaactgac 780
gctgaggctc gaaagtatgg gtagcaaaca ggattagata ccctggtagt ccataccgta 840
aacgatgaat gctaagtgtt ggagggtttc cgcccttcag tgctgcagct aacgcattaa 900
gcattccgcc tggggagtac ggccgcaagg ctgaaactca aaggaattga cgggggcccg 960
cacaagcggt ggagcatgtg gtttaattcg aagctacgcg aagaacctta ccaggtcttg 1020
acatactatg caaatctaag agattagacg ttcccttcgg ggacatggat acaggtggtg 1080
catggttgtc gtcagctcgt gtcgtgagat gttgggttaa gtcccgcaac gagcgcaacc 1140
cttattatca gttgccagca ttaagttggg cactctggtg agactgccgg tgacaaaccg 1200
gaggaaggtg gggatgacgt caaatcatca tgccccttat gacctgggct acacacgtgc 1260
tacaatggat ggtacaacga gttgcgaact cgcgagagta agctaatctc ttaaagccat 1320
tctcagttcg gattgtaggc tgcaactcgc ctacatgaag tcggaatcgc tagtaatcgc 1380
ggatcagcat gccgcggtga atacgttccc gggccttgta cacaccgccc gtcacaccat 1440
gagagtttgt aacacccaaa gtcggtgggg taacctttta ggaaccagcc gcctaaggtg 1500
ggacagatga ttagggtgaa gtcgtaacaa ggtagccgta ggagaa 1546
<210> 2
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
actcctacgg gaggcagcag 20
<210> 3
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
ggactachvg ggtwtctaat 20
Claims (6)
1.一种植物乳杆菌(Lactobacillus plantarum)Y44，其特征在于，所述植物乳杆菌(Lactobacillus plantarum)Y44于2018年8月21日，保藏于中国典型培养物保藏中心，菌株保藏号为CCTCC NO：M 2018558。
2.权利要求1所述的植物乳杆菌(Lactobacillus plantarum)Y44在制备用于缓解肥胖症状或抗高血脂症的药物或保健品中的应用。
3.根据权利要求2所述的应用，其特征在于，所述缓解肥胖包括缓解体重及脏器脂肪指数的增加。
4.根据权利要求2所述的应用，其特征在于，所述抗高血脂症包括原发性高血脂症和继发性高血脂症。
5.根据权利要求2所述的应用，其特征在于，所述缓解肥胖包括恢复高脂膳食引起的肠道微生物群失调，减少有害菌丰度、增加有益菌丰度。
6.根据权利要求2所述的应用，其特征在于，所述缓解肥胖症状包括降低肥胖引起的慢性结肠炎症。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010728709.9A CN111909869A (zh) | 2020-07-23 | 2020-07-23 | 植物乳杆菌y44及其在制备缓解肥胖或抗高血脂症药物或保健品中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010728709.9A CN111909869A (zh) | 2020-07-23 | 2020-07-23 | 植物乳杆菌y44及其在制备缓解肥胖或抗高血脂症药物或保健品中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111909869A true CN111909869A (zh) | 2020-11-10 |
Family
ID=73280774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010728709.9A Pending CN111909869A (zh) | 2020-07-23 | 2020-07-23 | 植物乳杆菌y44及其在制备缓解肥胖或抗高血脂症药物或保健品中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111909869A (zh) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112813003A (zh) * | 2021-02-08 | 2021-05-18 | 青岛海华莱康生物医药技术有限公司 | 一株植物乳杆菌及其在制备缓解高血脂症引发的疾病的药物或食品中的应用 |
| CN113249256A (zh) * | 2021-05-18 | 2021-08-13 | 江南大学 | 一株缓解雌激素相关代谢紊乱及肥胖的植物乳杆菌及应用 |
| CN113444669A (zh) * | 2021-07-27 | 2021-09-28 | 中国海洋大学 | 一株植物乳杆菌Lactobacillus plantarum F3-2及其应用 |
| CN114164142A (zh) * | 2021-11-08 | 2022-03-11 | 南京农业大学 | 具有缓解高脂膳食引起的非酒精性脂肪肝功能的植物乳杆菌q16 |
| CN114231443A (zh) * | 2021-11-29 | 2022-03-25 | 大连工业大学 | 一种植物乳杆菌复合菌及其在制备缓解肠道炎症或治疗溃疡性结肠炎复合益生菌中的应用 |
| CN114958652A (zh) * | 2022-04-26 | 2022-08-30 | 大连工业大学 | 一种含植物乳杆菌y44的复配发酵剂及其发酵复配乳 |
| CN115873761A (zh) * | 2022-11-10 | 2023-03-31 | 重庆第二师范学院 | 一种植物乳杆菌ksfy01及其应用 |
| IT202200011528A1 (it) * | 2022-05-31 | 2023-12-01 | Synbiotec S R L | Lactiplantibacillus plantarum IMC 510 per uso in un metodo per la prevenzione e il trattamento dell’obesità |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138110A (zh) * | 2016-01-29 | 2016-11-23 | 江南大学 | 一种改善肥胖的微生物菌剂及其制备方法 |
| WO2017204415A1 (ko) * | 2016-05-24 | 2017-11-30 | 경희대학교 산학협력단 | 혈당 조절 효능을 갖는 신규 유산균 및 이의 용도 |
| CN107760620A (zh) * | 2017-10-18 | 2018-03-06 | 天津科睿恒生物科技有限公司 | 一株改善易胖体质及子代体重的植物乳杆菌及应用 |
| CN108570436A (zh) * | 2017-12-14 | 2018-09-25 | 浙江大学 | 植物乳杆菌zjuf t17及其应用 |
| WO2019085521A1 (zh) * | 2017-11-03 | 2019-05-09 | 江南大学 | 一种具有抑制结直肠癌发生功能的植物乳杆菌及其用途 |
| CN110684701A (zh) * | 2019-11-19 | 2020-01-14 | 西南大学 | 植物乳杆菌s58及其在制备用于缓解肥胖的产品中的应用 |
| CN111254089A (zh) * | 2019-12-30 | 2020-06-09 | 杭州娃哈哈科技有限公司 | 一株具有减肥功能的植物乳杆菌及其应用 |
-
2020
- 2020-07-23 CN CN202010728709.9A patent/CN111909869A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138110A (zh) * | 2016-01-29 | 2016-11-23 | 江南大学 | 一种改善肥胖的微生物菌剂及其制备方法 |
| WO2017204415A1 (ko) * | 2016-05-24 | 2017-11-30 | 경희대학교 산학협력단 | 혈당 조절 효능을 갖는 신규 유산균 및 이의 용도 |
| CN107760620A (zh) * | 2017-10-18 | 2018-03-06 | 天津科睿恒生物科技有限公司 | 一株改善易胖体质及子代体重的植物乳杆菌及应用 |
| WO2019085521A1 (zh) * | 2017-11-03 | 2019-05-09 | 江南大学 | 一种具有抑制结直肠癌发生功能的植物乳杆菌及其用途 |
| CN108570436A (zh) * | 2017-12-14 | 2018-09-25 | 浙江大学 | 植物乳杆菌zjuf t17及其应用 |
| CN110684701A (zh) * | 2019-11-19 | 2020-01-14 | 西南大学 | 植物乳杆菌s58及其在制备用于缓解肥胖的产品中的应用 |
| CN111254089A (zh) * | 2019-12-30 | 2020-06-09 | 杭州娃哈哈科技有限公司 | 一株具有减肥功能的植物乳杆菌及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| YUAN GAO: "Physiological function analysis of Lactobacillus plantarum Y44 based on genotypic and phenotypic characteristics", 《J. DAIRY SCI.》 * |
| YUJUN LIU 等: "The ameliorative effect of Lactobacillus plantarum Y44 oral administration on in flammation and lipid metabolism in obese mice fed with a high fat diet", 《FOOD & FUNCTION》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112813003A (zh) * | 2021-02-08 | 2021-05-18 | 青岛海华莱康生物医药技术有限公司 | 一株植物乳杆菌及其在制备缓解高血脂症引发的疾病的药物或食品中的应用 |
| CN113249256A (zh) * | 2021-05-18 | 2021-08-13 | 江南大学 | 一株缓解雌激素相关代谢紊乱及肥胖的植物乳杆菌及应用 |
| CN113444669A (zh) * | 2021-07-27 | 2021-09-28 | 中国海洋大学 | 一株植物乳杆菌Lactobacillus plantarum F3-2及其应用 |
| CN114164142A (zh) * | 2021-11-08 | 2022-03-11 | 南京农业大学 | 具有缓解高脂膳食引起的非酒精性脂肪肝功能的植物乳杆菌q16 |
| CN114231443A (zh) * | 2021-11-29 | 2022-03-25 | 大连工业大学 | 一种植物乳杆菌复合菌及其在制备缓解肠道炎症或治疗溃疡性结肠炎复合益生菌中的应用 |
| CN114231443B (zh) * | 2021-11-29 | 2023-05-16 | 大连工业大学 | 一种植物乳杆菌复合菌及其在制备缓解肠道炎症或治疗溃疡性结肠炎复合益生菌中的应用 |
| CN114958652A (zh) * | 2022-04-26 | 2022-08-30 | 大连工业大学 | 一种含植物乳杆菌y44的复配发酵剂及其发酵复配乳 |
| CN114958652B (zh) * | 2022-04-26 | 2024-04-19 | 大连工业大学 | 一种含植物乳杆菌y44的复配发酵剂及其发酵复配乳 |
| IT202200011528A1 (it) * | 2022-05-31 | 2023-12-01 | Synbiotec S R L | Lactiplantibacillus plantarum IMC 510 per uso in un metodo per la prevenzione e il trattamento dell’obesità |
| WO2023233208A1 (en) * | 2022-05-31 | 2023-12-07 | Synbiotec S.R.L. | Lactiplantibacillus plantarum imc 510 for use in a method for the prevention and treatment of obesity |
| CN115873761A (zh) * | 2022-11-10 | 2023-03-31 | 重庆第二师范学院 | 一种植物乳杆菌ksfy01及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111909869A (zh) | 植物乳杆菌y44及其在制备缓解肥胖或抗高血脂症药物或保健品中的应用 | |
| CN114317320B (zh) | 一种短双歧杆菌207-1及其应用 | |
| CN108728382B (zh) | 一株具降胆固醇及促进肠道短链脂肪酸产生能力的植物乳杆菌及其应用 | |
| CN110452842B (zh) | 乳双歧杆菌nbk-W13及其应用 | |
| CN112813003B (zh) | 一株植物乳杆菌及其在制备缓解高血脂症引发的疾病的药物或食品中的应用 | |
| CN114107088B (zh) | 一种罗伊氏乳杆菌lrsy523及其应用 | |
| CN114181864B (zh) | 一种鼠李糖乳杆菌hf01及其应用 | |
| CN109628346B (zh) | 发酵乳杆菌cqpc04及其在制备发酵食品中的应用 | |
| CN110484459B (zh) | 一株植物乳杆菌及其应用 | |
| CN114717129A (zh) | 一株鼠李糖乳杆菌及其在预防和缓解便秘症状中的应用 | |
| CN116445356A (zh) | 一种调节肠道菌群及增强免疫力的动物双歧杆菌乳亚种ba67及其应用 | |
| CN111903983A (zh) | 植物乳杆菌Lactobacillus plantarum Y44在制备抗氧化益生菌产品中的应用 | |
| CN113528367B (zh) | 一株具有预防腹泻和降解胆固醇功能的凝结芽孢杆菌 | |
| CN117100774A (zh) | 嗜酸乳杆菌jyla-16在制备治疗胆结石的产品中的应用 | |
| CN115992076B (zh) | 一株降血糖功能发酵乳杆菌及其应用 | |
| CN109609415B (zh) | 一种甲烷菌及其应用 | |
| CN114053310B (zh) | 普通拟杆菌益生菌cgmcc no.17140在制备降脂药物中的应用 | |
| CN113388554B (zh) | 一株植物乳杆菌shy130及其缓解糖尿病的应用 | |
| CN115478036A (zh) | 一株缓解非酒精性脂肪肝的黏膜粘液乳杆菌及其应用 | |
| CN112812989B (zh) | 一种能够缓解银屑病的青春双歧杆菌及其应用 | |
| CN113249256A (zh) | 一株缓解雌激素相关代谢紊乱及肥胖的植物乳杆菌及应用 | |
| CN117025492B (zh) | 一种减轻宠物肥胖的嗜热链球菌jyst-81及其应用 | |
| Shihab et al. | Ameliorative Effect of Probiotic Strains, Lactobacillus acidophilus and Lactobacillus bulgaricus against Acetic Acid-Induced Inflammation in the Mouse Colon | |
| Rahimkhani et al. | Fecal microbial flora in colorectal cancer | |
| CN117903995A (zh) | 一株植物乳杆菌ym-4-3及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201110 |
|
| WD01 | Invention patent application deemed withdrawn after publication |